Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof

Abstract

A fusion gene prepared by combining the modified human papillomavirus 16 (HPV-16) E6 / E7 gene with the reformed branched tubercle bacillus' heat shock protein 70 (TBhsp70) gene, its preparing process, its efficient expression carrier and its configuration, the recombinant protein vaccine prepared from said fusion gene, and the application of said fusion gene and recombinant protein vaccine in preparing the medicines for preventing and treating the tumor associated with human papillomavirus are disclosed.

Description

Technical field [0001] The invention relates to a human papillomavirus and heat shock protein fusion gene, its expression vector and a recombinant protein vaccine, in particular to a modified human papillomavirus type 16 (HPV-16) E6 / E7 and a modified Mycobacterium tuberculosis fever Shock protein 70 (TBhsp70) fusion gene, the preparation method of the fusion gene, the construction of an efficient expression vector containing the fusion gene and the expression vector, the fusion protein obtained by using the fusion gene, and the preparation of the fusion gene and the fusion protein Prevention and treatment of human papillomavirus related diseases and the application of tumor drugs. Background technique [0002] Malignant tumors are common and frequently-occurring diseases that seriously endanger human health. At present, the three conventional treatment methods in tumor treatment: surgery, radiotherapy, and chemotherapy have developed to a certain extent, but surgical resection is...

AI Technical Summary

Problems solved by technology

For example, although the classic aluminum adjuvant has been used in combination with ordinary vaccines to improve antibody levels and safety, it has been proven in practice for a long time, but it has no effect on the ability of genetically engineered proteins or polypeptides to induce cellular immunity. Its mechanism of action is poorly understood, making it difficult to meet the needs of new vaccines; for another example, although incomplete Freund's adjuvant (IFA) has been proved to be one of the most successful adjuvants in both animals and humans, its possible People still worry about side effects, such as: nodules are often formed when applied locally, and even cysts are formed by liquefaction. It has been reported that it has tumorigenic effects in male Swiss mice (BullWHO, 1969; 41:617-621), but in BALB / c and Not tumorigenic in C57BL / 6 mice, so safety concerns remain

Finally, although a variety of new adjuvants have been developed, the safety and mechanism of action still need to be further studied

Images